How Did the First Protein Translocators Integrate into the ER Membrane?

  • Thread starter nautica
  • Start date
  • Tags
    Protein
In summary, proteins are integrated into the ER membrane through the use of protein translocators, which are membrane proteins themselves. It is believed that some proteins may not require translocators due to their size or structure, while others may have their own translocation domains. It is also possible that some eukaryotic ER components have self translocators specific for the ER membrane. In addition, there is a type V secretion pathway known as Autotransporter protein secretion system, which may be a similar mechanism for protein translocation. This information was discussed in the conversation, along with the mention of 2004 award nominations in the PF Community section.
  • #1
nautica
Membrane proteins are integrated into the ER membrane by means of protein translocators, which are themselves membrane proteins.

So how would the first protein translocators become incorporated into the ER membrane?

Nautica
 
Biology news on Phys.org
  • #2
Aww, c'mon, why don't you ask a hard question for a change? :smile:

I truly have no idea, but could venture a wild guess that perhaps some don't require translocators due to their size or structure, but it is only a wild guess.
 
  • #3
It could just be that they very much LIKE to be in the membrane, so as moonbear said they just don't need translocators. Proteins that WOULD need translocators are those that have very hydrophilic chains that thus normally would never cross the membrane by themselves.
 
  • #4
I do know that some secreted proteins in bacteria have their own translocation domains, ie. type V secretion systems. Wouldn't be too far fetched to say that some eukaryotic ER components could encode self translocators specific for ER membranes, though I don't know of any specific examples.
 
  • #5
I would have to agree with none there must be a type v -like mechanism for protein transltor. I will do more research.
 
  • #6
Yes, that is a thought. I'll check on that also.

Thanks
nautica
 
  • #7
btw
Moonbear, you sig speaks of voting. What are we voting for?

nautica
 
  • #8
nautica said:
btw
Moonbear, you sig speaks of voting. What are we voting for?

nautica

In the PF Community section, there are 2004 award nominations up for voting.
 
  • #9
iansmith said:
there must be a type v -like mechanism
What mechanism would that be?
 
  • #10
Monique said:
What mechanism would that be?

good question
 
  • #11
Type V secretion pathway are also known as Autotransporter protein secretion system.

http://www.horizonpress.com/cimb/abstracts/v6/09.html
http://pasteur.fontismedia.com/infiles/out/res031162.pdf
 
Last edited by a moderator:
  • #12
sweet, good info.

Thanks
Nautica
 

FAQ: How Did the First Protein Translocators Integrate into the ER Membrane?

What are protein translocators?

Protein translocators are cellular structures responsible for transporting proteins across cell membranes. They are found in both prokaryotic and eukaryotic cells and play a crucial role in the proper functioning of cells.

How do protein translocators work?

Protein translocators work by recognizing specific signals on the proteins, such as signal peptides, and using energy to transport them across the membrane. They can transport proteins in both directions, depending on the needs of the cell.

What types of protein translocators are there?

There are two main types of protein translocators: Sec and Tat. Sec translocators are found in all cells and transport proteins in an unfolded state, while Tat translocators are only found in some bacteria and can transport proteins in a folded state.

What is the role of protein translocators in disease?

Protein translocators play a crucial role in the development of certain diseases. For example, defects in the Sec translocator have been linked to cystic fibrosis, and malfunctioning Tat translocators have been associated with bacterial infections.

Can protein translocators be targeted for medical treatments?

Yes, researchers are actively investigating the potential of targeting protein translocators for medical treatments. This could involve developing drugs that inhibit or enhance the function of specific translocators, potentially leading to new treatments for diseases caused by translocator dysfunction.

Back
Top